Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
89 participants
OBSERVATIONAL
2020-10-29
2022-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
NCT04546542
Functional Analysis of Salivary Glands and Correlation With Sialoscintigraphy in Sjogren's Syndrome
NCT06536075
Salivary Markers in Patients With Xerostomia
NCT03156569
Diagnostic Interest of the Buccal Schirmer Test in Xerostomia During Sjögren's Syndrome: XERODIAG
NCT06530940
The Pathogenesis and Natural History of Sjogren's Disease
NCT01425892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sjögren's syndrome (SS) is a chronic autoimmune disease that primarily affects the exocrine glands, resulting in their functional impairment. In SS, lymphocytic infiltration of salivary and lacrimal glands, and deposition of several types of autoantibodies, mainly anti-SS-A (anti-Ro) and anti-SS-B (anti-La), lead to chronic inflammation, with xerostomia and keratoconjunctivitis sicca. In its primary form (pSS), SS does not involve additional connective tissue diseases. SS presents in association with other rheumatic autoimmune diseases, mainly rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis.
Obviously, a prerequisite step in answering this critical question was to depict the change of inflammatory biomarkers of hematologic indices and disease activity progression in a detailed and comprehensive manner, and actually there were several studies aimed at answering this question. Along the hematologic indices field, most of the studies agreed that RDW was critical parameter in SS activity indication.
As in most autoimmune diseases, environmental, hormonal and genetic factors are implicated in SS pathogenesis. have been shown to be a good serum marker in primary SS (pSS). All these indicated a potential linkage between systemic inflammation and the risk of SS. However, sparse evidence has been available on this association between the hematologic indices and SS. The aim of the present study, therefore, was to evaluate the association between systemic inflammation indices and SS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
89 SS patients
The medical records were analyzed retrospectively about the 89 patients with first onset of SS (SS group)
blood sample analysis
All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
89 healthy control subjects
The medical records were analyzed retrospectively about the 89 age- and gender-matched individuals (Control group) who presented with normal control.
blood sample analysis
All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample analysis
All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* without systemic diseases, such as hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease,
* without malignant tumors,
* without renal failure,
* without liver diseases,
* without anemia,
* without smoking and alcohol consumption,
* without active infection,
* without other autoimmune diseases,
* without medicine usage that could influence the blood coagulation state,
* without a history of concurrent ocular diseases or trauma,
* without any surgery within three months.
Exclusion Criteria
* malignant tumor,
* renal failure,
* liver diseases,
* anemia,
* smoking and alcohol consumption,
* active infection,
* other autoimmune diseases,
* medicine usage that could influence the blood coagulation state,
* a history of concurrent ocular diseases or trauma,
* any surgery within three months.
45 Years
67 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Eye Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Wang
Role: STUDY_CHAIR
Tianjin Eye Hospital and Eye Institute, Nankai University Affiliated Eye Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A. Clinical and immunological parameters of Sjogren's syndrome. Autoimmun Rev. 2018 Oct;17(10):1053-1064. doi: 10.1016/j.autrev.2018.05.005. Epub 2018 Aug 10.
Yildiz F, Gokmen O. Haematologic indices and disease activity index in primary Sjogren's syndrome. Int J Clin Pract. 2021 Mar;75(3):e13992. doi: 10.1111/ijcp.13992. Epub 2021 Jan 19.
Hu ZD, Sun Y, Guo J, Huang YL, Qin BD, Gao Q, Qin Q, Deng AM, Zhong RQ. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjogren's syndrome. Clin Biochem. 2014 Dec;47(18):287-90. doi: 10.1016/j.clinbiochem.2014.08.022. Epub 2014 Sep 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY202226
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.